goal of new rating boards for innovative therapies is to provide patients throughout Austria with equal access to this area. But the established rules of procedure raise concerns that there will be delays in access to important therapies.
How this can be avoided is the topic of the Rare Diseases Dialogue and the virtual press conference. The following experts are available to media representatives in advance:
- Univ.-Prof. Dr. Michael Freissmuth: Head of the Center for Physiology and Pharmacology, Medical University of Vienna
- Dr. Sylvia Nanz: Medical Director, Pfizer Corporation Austria | Vice Chair, PHARMIG Standing Committee Rare Diseases
- Univ.-Prof. Dr. Barbara Plecko: Head of the Clinical Department of General Pediatrics, Univ. Clinic for Pediatrics and Adolescent Medicine, LKH University Hospital Graz
- Mag. Elisabeth WeigandMBA: Management, Pro Rare Austria
Moderation: Peter RichterPHARMIG
Datum: November 12, 2024, 11:00 a.m., via Microsoft Teams
Please register with Peter Richter at peter.richter@pharmig.at. You will receive the link to the event after registration.
The Rare Diseases Dialog will take place on November 12, 2024 at 4:00 p.m. in the Urania Vienna. Participation is possible both on site and virtually.
OTS ORIGINAL TEXT PRESS RELEASE UNDER THE EXCLUSIVE RESPONSIBILITY OF THE SENDER FOR CONTENT – WWW.OTS.AT | PHA